Following the news of a strategic partnership, Fractyl Health, Inc. (NASDAQ: GUTS) shares surged 44.72% to end at $2.88 in the most recent trading session. The increase comes after Fractyl Health and Bariendo Inc., a cutting-edge platform providing affordable, long-term endoscopic therapies for obesity, signed a non-binding Letter of Intent (LOI).
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
The letter of intent describes a potential collaboration to investigate the use of GUTS’ experimental Revita technique as a long-term weight-maintenance strategy following the cessation of GLP-1-based medications.
Focus on Post-GLP-1 Weight Maintenance
The goal of the planned partnership is to establish Revita as a crucial part of obesity management plans, particularly as a long-term “off-ramp” after GLP-1 treatment. The agreement emphasizes the pressing need for a non-pharmacological, procedure-based option in view of rising concerns about fast weight recovery following GLP-1 medication discontinuation.
In order to restore the disease-causing alterations in the gut linked to obesity and metabolic dysfunction, Revita is an outpatient endoscopic technique that targets the duodenal lining. It may be the first disease-modifying therapy to target a major contributor to obesity if the FDA approves it.
Upcoming Clinical Milestones for Revita
Fractyl Health is currently advancing Revita through its pivotal clinical program, with three major data readouts scheduled: open-label data from the REVEAL-1 Cohort in June 2025; midpoint data from the REMAIN-1 Midpoint Cohort in Q3 2025; and primary endpoint data from the REMAIN-1 Pivotal Cohort expected in late 2026.
The purpose of these trials is to show that Revita can assist patients in maintaining their weight reduction and enhancing their metabolic health following the termination of GLP-1 medication.
Shared Vision for Scalable, Durable Obesity Care
Fractyl Health’s (GUTS) endeavors to provide scalable metabolic therapies for outpatients are in line with Bariendo’s physician-driven platform, which covers a broad network of endoscopy facilities in the United States. The companies plan to collaborate on clinical workflow design, provider education, economic modeling, and referral systems in anticipation of FDA approval.
This partnership marks a significant step toward commercial readiness and reflects strong interest from both patients and providers in sustainable, drug-free obesity care.
